• Patients voluntarily enrolled in the study and signed an informed consent form

• 18-75 years old, male and female gender are not limited

• Gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction as determined by pathologic histology

• Clinical staging of II-III/T3-4aNxM0 (AJCC 8th edition cTNM staging of gastric cancer)

• Clinically judged to be surgically resectable

• have at least one measurable lesion (according to the requirements of RECISTv1.1, the long diameter of spiral CT scan of this measurable lesion is ≥10mm or the short diameter of enlarged lymph node is ≥15mm)

• No other anti-tumor therapy has been received

• ECOG score:0\

‣ 1

• Good function of major organs

⁃ No active hepatitis B virus (HBV) infection

⁃ Women of childbearing potential must have had a negative blood pregnancy test within 3 days prior to randomization and be willing to use an appropriate method of contraception during the trial and for 6 months after completion of treatment. For men, surgical sterilization or agreement to use an appropriate method of contraception during the study and for 3 months after completion of treatment.